Social media

ICON and Advarra have entered a new partnership to introduce a ‘research-ready’, connected site network model that will transform how clinical trials are operationalised globally. The model will integrate ICON’s clinica...

Meet with ICON experts at the GLP-1-Based Therapeutics Summit to gain valuable insights on obesity clinical development and learn about our ready-to-deploy infrastructure designed to accelerate obesity and comorbidity pr...

How to navigate EU MAA Regulations and Registration For Chinese pharma and biotech companies looking to expand into the European Union’s market of over 450 million people, the first step is to understand the significant...

How to navigate EU MAA Regulations and Registration. Regulatory legislation in China differs substantially from that of the European Union. For Chinese biotech companies looking to enter the market it is critical to as...

ICON is heading to #AMCP2026 from 13–16 April, and our team is looking forward to engaging with leaders across the managed care and market access community. Visit us at booth \#1412 to learn how ICON’s evidence generatio...

ICON is heading to #AMCP2026 from 13–16 April, and our team is looking forward to engaging with leaders across the managed care and market access community. Visit us at booth #1412 to learn how ICON’s evidence generation...

Earlier this month, our teams across ICON came together around the world to celebrate International Women’s Day. From team celebrations and office events to shared moments of reflection, this year’s theme, Give to Gain,...

Accellacare, ICON’s clinical research network, offers a wide range of stand-alone and integrated solutions to increase patient access to innovative treatments. Meet us at #WorldVaccineCongress, booth 222 to learn how o...

Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...

Deepali Suri, President of ICON Biotech, has been published in Pharmaceutical Executive. Her article draws on insights from 163 biotech leaders across North America, EMEA and APAC, supported by a supplementary survey o...

2026 will be a pivotal year for Europe’s HTA landscape. The Work Program forecasts: - \~50 JCAs for medicinal products - The first assessments of high risk medical devices - A fully operational HTA IT platform - More pre...

2026 will be a pivotal year for Europe’s HTA landscape. The Work Program forecasts: - ~50 JCAs for medicinal products - The first assessments of high risk medical devices - A fully operational HTA IT platform - More pred...